deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-22. Numbers and descriptions here follow the published literature rather than marketing material.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
It was not until the beginning of the 19th century that it became clear that reptiles and amphibians are, in fact, quite different animals, and P.A. Latreille erected the class Batracia (1825) for the latter, dividing the tetrapods into the four familiar classes of reptiles, amphibians, birds, and mammals. The British anatomist T.H. Huxley made Latreille's definition popular and, together with Richard Owen, expanded Reptilia to include the various fossil "antediluvian monsters", including dinosaurs and the mammal-like (synapsid) Dicynodon he helped describe. This was not the only possible classification scheme: In the Hunterian lectures delivered at the Royal College of Surgeons in 1863, Huxley grouped the vertebrates into mammals, sauroids, and ichthyoids (the latter containing the fishes and amphibians). He subsequently proposed the names of Sauropsida and Ichthyopsida for the latter two groups. In 1866, Haeckel demonstrated that vertebrates could be divided based on their reproductive strategies, and that reptiles, birds, and mammals were united by the amniotic egg. The terms Sauropsida ("lizard faces") and Theropsida ("beast faces") were used again in 1916 by E.S. Goodrich to distinguish between lizards, birds, and their relatives on the one hand (Sauropsida) and mammals and their extinct relatives (Theropsida) on the other. Goodrich supported this division by the nature of the hearts and blood vessels in each group, and other features, such as the structure of the forebrain.
In clinical trials, an event or outcome that can be measured objectively to determine whether the intervention being studied is beneficial. The endpoints of a clinical trial are usually included in the study objectives. Some examples of endpoints are survival, improvements in quality of life, relief of symptoms, and disappearance of the tumor. (NCI) Overall outcome that the protocol is designed to evaluate. Common endpoints are severe toxicity, disease progression, or death. (NLM) Enrolling
A day later he confirmed that he would stand and was listed as a candidate, decrying Green Party leader Zack Polanski for former comments against Jeremy Corbyn and Polanski's stance on social issues. His decision to stand sparked a controversy within his party, with deputy leader Chris Williamson resigning and urging the party to support Polanski.
In 2018, El Salvador cut diplomatic ties with Taiwan and recognized the People's Republic of China as China's legitimate government. This led to Bukele and the United States accusing China of interfering in Salvadoran and Latin American politics. Despite Bukele's criticism of China before becoming president, Vice President Félix Ulloa stated in May 2019 that Bukele's government would not restore diplomatic relations with Taiwan. In December 2019, Bukele met Chinese leader Xi Jinping in Beijing and signed a "gigantic" infrastructure agreement with China for an unknown amount of money. El Salvador and China have cooperated on infrastructure projects in El Salvador such as the National Library of El Salvador (completed in November 2023) and the National Stadium of El Salvador (construction began in November 2023). In November 2022, Bukele announced that El Salvador and China had begun negotiations for a free trade agreement between the countries. China donated fertilizer and wheat flour to El Salvador and, according to a Salvadoran government official, offered to buy El Salvador's external bond debt. Bukele stated that a free trade agreement with China was "very important" because El Salvador had been "isolated from [the] potential" of China's economic strength.
== Sequels == Half-Life 2: Episode Two was released in 2007. Episode Three was scheduled for release by Christmas 2007, but was canceled as Valve found the episodic model contrary to their growing ambition for new installments, and needed to dedicate resources to Left 4 Dead, which was nearing completion. After canceling several further Half-Life projects, Valve released a prequel, Half-Life: Alyx, in 2020.
Sources: en.wikipedia.org
== Function == Parafollicular cells secrete calcitonin, a hormone that participates in the regulation of calcium metabolism. Calcitonin lowers blood levels of calcium by inhibiting the resorption of bone by osteoclasts, and its secretion is increased proportionally with the concentration of calcium. Parafollicular cells are also known to secrete in smaller quantities several neuroendocrine peptides such as serotonin, somatostatin or CGRP. They may also have a role in regulating thyroid hormones production locally, as they express thyrotropin-releasing hormone.
==== Breastfeeding ==== Low concentrations of ceftriaxone are excreted in breast milk that are "not expected to cause adverse effects in breastfed infants." The manufacturer recommends that caution be exercised when administering ceftriaxone to women who breastfeed.
==== Art ==== In 2008, the artist Roger Hiorns filled an abandoned waterproofed council flat in London with 75,000 liters of copper(II) sulfate water solution. The solution was left to crystallize for several weeks before the flat was drained, leaving crystal-covered walls, floors and ceilings. The work is titled Seizure. Since 2011, it has been on exhibition at the Yorkshire Sculpture Park.
The Beauty is an American science fiction body horror television series created by Ryan Murphy and Matthew Hodgson. It is based on the comic book The Beauty, written by Jeremy Haun and Jason A. Hurley, and stars Evan Peters, Anthony Ramos, Jeremy Pope, Rebecca Hall, and Ashton Kutcher. The series premiered on FX and Hulu on January 21, 2026. In July 2026, it was reported that the entire cast had been released so the actors can pursue other projects, leaving the future of the series unclear.
Sources: en.wikipedia.org
=== Pharmacodynamics === Romergoline shows high affinity for the dopamine D2 receptor (Ki = 6.5 nM), α2-adrenergic receptor (Ki = 4.0 nM), and serotonin 5-HT1A receptor (Ki = 4.0 nM). It also possesses moderate (submicromolar) affinity for the dopamine D1 receptor (Ki = 55 nM) and ketanserin-labeled serotonin 5-HT2 receptor (Ki = 24 nM). Conversely, the drug shows slight or negligible affinity for the α1-adrenergic receptor (Ki = 113 nM), muscarinic acetylcholine receptors (Ki = >10,000 nM), and sigma receptors (Ki = >10,000 nM). Romergoline is said to act as both a dopamine receptor agonist and antagonist, depending on the circumstances. More specifically, the drug is said to act as a D2 receptor silent antagonist under normal dopamine-replete circumstances, but in a dopamine-depleted state, it acts as a powerful dopamine D1 receptor full agonist. This transformation of the drug's activity is thought to be due to development of dopamine D1 receptor supersensitivity with dopamine depletion. Romergoline produces hypolocomotion in rodents and monkeys, inhibits apomorphine-induced climbing behavior in rodents, causes antiemetic effects in dogs, strongly increases prolactin levels in rodents, and antagonizes amphetamine-induced toxicity in rodents. With dopamine depletion however, romergoline induces hyperlocomotion and contralateral turning behavior in 6-hydroxydopamine-lesioned rodents, reverses MPTP-induced akinesia and parkinsonism in monkeys, and reverses reserpine-induced hypokinesia.
1 November – A pooled analysis indicates that globally over half of all preschool-aged children and over two-thirds of all nonpregnant women of reproductive age are deficient in at least one of three micronutrients each. The study notes required data is scarce and such deficiencies can constrain physical and (neurocognitive) development and compromise health. 2 November – Scientists show that cells move faster in thicker (higher viscosity) fluids. Cancer cells can form memory of extracellular fluid, helping them to form distant cancerous colonies more efficiently when exposed to fluids of higher viscosities. 3 November – Astronomers using the IXPE space observatory report that 4U 0142+61, a magnetar found 13,000 light-years from Earth, likely has a solid surface with no atmosphere. 4 November – The discovery of Gaia BH1, a binary system containing what is likely the closest known black hole to Earth, is reported by astronomers in the U.S. 6–18 November – The 2022 United Nations Climate Change Conference (COP27) on climate change mitigation takes place in Sharm el-Sheikh, Egypt. 7 November The first clinical trial of laboratory-grown red blood cells transfused into people begins. Scientists warn about summarized effects of climate change on insects, among other novel stressors, which may "drastically reduce our ability to build a sustainable future based on healthy, functional ecosystems", providing several recommended mitigation options. The development of organic artificial neurons that function in and with biological systems, partly (see e.g.
== Molecular weight distribution in linear polymerization == The product of a polymerization is a mixture of polymer molecules of different molecular weights. For theoretical and practical reasons, it is of interest to discuss the distribution of molecular weights in a polymerization. The molecular weight distribution (MWD) had been derived by Flory by a statistical approach based on the concept of equal reactivity of functional groups.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.